Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison-Reference-Cited by-同舟云学术

Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison

Published:2018-11-20 Issue:1 Volume:22 Page:71-84
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Taheri Saeed¹^ORCID,Sahraian Mohammad Ali²^ORCID,Yousefi Nazila¹^ORCID

Affiliation:

1. Department of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Science, Tehran, Iran;

2. MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Funder

Sanofi pharmaceutical Company

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1543189

Reference102 articles.

1. Multiple sclerosis International federation [Internet]. London, UK. Available at: https://www.msif.org/ [Last accessed January 2017]

2. Facts about MS [Internet]. Florida, USA. Available at: http://msfocus.org/Facts-About-MS.aspx [Last accessed January 2017]

3. Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study

4. A prospective study of the financial costs of multiple sclerosis at different stages of the disease

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain;Journal of Medical Economics;2022-12-13

2. Cost-Effectiveness of Multiple Sclerosis Therapies – A Literature Review;Acta Medica Bulgarica;2022-12-01

3. Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease;The European Journal of Health Economics;2022-05-20

4. Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis;BMC Health Services Research;2022-01-28

5. A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa;Applied Health Economics and Health Policy;2021-12-21